ARMP net incomeQ2 2026$74.14M
ARMP net income was $74.14M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$16.30M a year earlier. For the full fiscal 2025 it was -$173.80M, compared with -$18.92M in fiscal 2024.
Armata Pharmaceuticals Inc. (ARMP) financials
For the twelve months ended Jun 30, 2026, Armata Pharmaceuticals Inc. reported -$192.18M of net income.
- Net income, TTM
- -$192.18M
- Free cash flow, TTM
- -$25.79M
- Cash
- $23.95M
- Market cap
- $139.4M
FY2016FY2025
FY2016FY2025
ARMP revenue and earnings growth
ARMP EPSQ2 2026-$0.27
ARMP diluted EPS was -$0.27 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$4.80.
ARMP free cash flowQ2 2026-$8.68M
ARMP free cash flow was -$8.68M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.36M a year earlier. For the full fiscal 2025 it was -$26.30M, compared with -$39.43M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $23.72M | $34.43M | $33.77M | $35.02M | $20.02M | $14.44M | $9.82M | $8.37M | $2.88M | $5.68M |
| Selling, general and admin | $12.41M | $13.18M | $11.65M | $7.44M | $8.28M | $7.97M | $9.27M | $2.52M | $7.59M | $8.41M |
| Operating income | -$36.63M | -$42.44M | -$40.89M | -$36.95M | -$23.82M | -$21.59M | -$19.75M | -$17.66M | -$16.16M | -$23.38M |
| Interest expense | - | - | - | $0 | $64.0K | $628.0K | $931.0K | $1.01M | - | $6.0K |
| Pre-tax income | -$173.80M | -$18.92M | -$69.05M | -$36.9K | -$23.16M | -$22.18M | -$19.48M | -$16.70M | -$14.14M | -$19.39M |
| Income tax | - | - | - | - | - | - | - | -$328.0K | -$1.30M | -$556.0K |
| Net income | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.70M | -$12.84M | -$18.84M |
| EPS, basic | -$4.80 | -$0.52 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.49 | -$3.59 | -$2.01 | -$24.67 |
| EPS, diluted | -$4.80 | -$0.89 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.55 | -$3.59 | -$2.18 | -$24.67 |
| Diluted shares | 36.2M | 59.1M | 36.1M | 34.3M | 24.1M | 16.4M | 8.0M | 4.7M | 6.6M | 983,846 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.69M | $14.77M | $19.24M | $20.81M | $11.49M | $10.85M | $6.73M | $10.46M | $12.28M | $5.13M |
| Receivables | - | - | - | - | - | - | - | - | - | $12.0K |
| Current assets | $10.67M | $11.31M | $19.15M | $27.05M | $14.99M | $10.85M | $6.66M | $10.36M | $5.38M | $6.31M |
| Goodwill | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | - | - | - |
| Total assets | $76.88M | $86.44M | $98.36M | $95.83M | $69.77M | $39.52M | $25.45M | $14.54M | $11.14M | $18.15M |
| Current liabilities | $8.95M | $48.25M | $16.46M | $24.87M | $4.81M | $6.71M | $4.88M | $2.03M | $1.97M | $3.54M |
| Total liabilities | $295.48M | $134.46M | $130.43M | $59.75M | $44.37M | $20.66M | $10.86M | $6.85M | $3.41M | $8.43M |
| Shareholders' equity | -$218.60M | -$48.02M | -$32.06M | $36.08M | $25.40M | $18.86M | $14.59M | $7.69M | $24.34M | $9.72M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.76M | -$37.55M | -$47.42M | -$32.48M | -$23.57M | -$18.27M | -$15.58M | -$10.63M | -$9.19M | -$10.61M |
| Capital expenditures | $542.0K | $1.88M | $8.14M | $2.21M | $1.30M | $824.0K | $224.0K | $875.0K | $58.0K | $279.0K |
| Free cash flow | -$26.30M | -$39.43M | -$55.57M | -$34.69M | -$24.88M | -$19.09M | -$15.81M | -$11.50M | -$9.25M | -$10.88M |
| Investing cash flow | -$542.0K | -$1.88M | -$8.13M | -$2.21M | -$1.30M | -$824.0K | $2.88M | $8.81M | -$58.0K | -$279.0K |
| Financing cash flow | $25.61M | $34.96M | $53.99M | $44.02M | $25.52M | $23.21M | $8.97M | $12.45M | $8.67M | $7.23M |
| Dividends paid | - | - | - | - | - | - | - | - | - | $80.0K |
| Stock-based compensation | $2.61M | $2.89M | $938.0K | $3.10M | $2.88M | $3.48M | $4.27M | $46.0K | $700.0K | $2.00M |
| Depreciation and amortization | - | $1.32M | $972.0K | $892.0K | - | - | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | - | - | - | -102.3% | -91.2% | -117.6% | -133.5% | -217.1% | -52.7% | -193.7% |
| Return on assets | -226.1% | -21.9% | -70.2% | -38.5% | -33.2% | -56.1% | -76.5% | -114.8% | -115.3% | -103.8% |
| Current ratio | 1.19 | 0.23 | 1.16 | 1.09 | 3.11 | 1.62 | 1.36 | 5.10 | 2.74 | 1.78 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $7.59M | $6.11M | $6.07M | $5.82M | $6.39M | $5.43M | $8.45M | $9.48M | $8.47M | $8.02M | $7.93M | $7.98M |
| Selling, general and admin | $5.24M | $3.46M | $3.43M | $3.11M | $2.62M | $3.25M | $3.32M | $3.24M | $3.44M | $3.18M | $3.18M | $3.58M |
| Operating income | -$10.31M | -$8.79M | -$13.82M | -$7.78M | -$6.84M | -$8.19M | -$10.54M | -$9.76M | -$11.91M | -$10.23M | -$9.58M | -$10.34M |
| Interest expense | - | - | - | - | - | - | - | - | $2.72M | $1.82M | - | $1.18M |
| Income tax | $0 | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 |
| Net income | $74.14M | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | $2.60M | -$5.48M | $8.99M | -$25.02M | -$19.85M | -$31.16M |
| EPS, basic | $2.02 | -$3.16 | - | -$0.74 | -$0.45 | -$0.18 | - | -$0.15 | $0.25 | -$0.69 | - | -$0.86 |
| EPS, diluted | -$0.27 | -$3.16 | - | -$0.74 | -$0.45 | -$0.20 | - | -$0.15 | -$0.25 | -$0.69 | - | -$0.86 |
| Diluted shares | 62.0M | 36.5M | - | 36.2M | 36.2M | 59.5M | - | 36.2M | 58.2M | 36.1M | - | 36.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $23.95M | $4.75M | $8.69M | $14.76M | $4.33M | $11.69M | $14.77M | $17.14M | $26.41M | $37.86M | $19.24M | $23.96M |
| Current assets | $27.16M | $5.95M | $10.67M | $16.93M | $7.52M | $13.17M | $11.31M | $22.39M | $30.90M | $41.72M | $19.15M | $36.59M |
| Goodwill | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M |
| Total assets | $89.95M | $69.80M | $76.88M | $89.52M | $80.79M | $87.25M | $86.44M | $98.24M | $108.31M | $120.36M | $98.36M | $112.76M |
| Current liabilities | $250.20M | $9.23M | $8.95M | $139.95M | $120.08M | $110.54M | $48.25M | $118.20M | $123.18M | $110.05M | $16.46M | $21.88M |
| Total liabilities | $321.12M | $381.39M | $295.48M | $185.10M | $150.29M | $141.03M | $134.46M | $149.21M | $154.41M | $176.87M | $130.43M | $125.15M |
| Shareholders' equity | -$231.17M | -$311.59M | -$218.60M | -$95.59M | -$69.50M | -$53.78M | -$48.02M | -$50.97M | -$46.10M | -$56.51M | -$32.06M | -$12.39M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.67M | -$5.78M | -$6.67M | -$4.30M | -$7.21M | -$7.58M | -$7.93M | -$8.86M | -$10.18M | -$10.58M | -$8.11M | -$9.69M |
| Capital expenditures | $17.0K | $63.0K | $52.0K | $242.0K | $149.0K | $99.0K | -$77.0K | $340.0K | $1.37M | $250.0K | $2.40M | $3.51M |
| Free cash flow | -$8.68M | -$5.84M | -$6.73M | -$4.54M | -$7.36M | -$7.68M | -$8.00M | -$9.20M | -$11.54M | -$10.83M | -$10.51M | -$13.20M |
| Investing cash flow | -$17.0K | -$63.0K | -$52.0K | -$242.0K | -$149.0K | -$99.0K | $77.0K | -$340.0K | -$1.37M | -$250.0K | -$2.39M | -$3.51M |
| Financing cash flow | $27.88M | $641.0K | $658.0K | $14.97M | $0 | $9.99M | $0 | -$61.0K | $88.0K | $34.93M | -$43.0K | $24.80M |
| Stock-based compensation | $3.39M | $1.07M | $632.0K | $622.0K | $575.0K | $781.0K | $354.0K | $670.0K | $1.33M | $534.0K | $193.0K | -$373.0K |
| Depreciation and amortization | - | - | - | $370.0K | $366.0K | $377.0K | $380.0K | $313.0K | $315.0K | $317.0K | $293.0K | $221.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.11 | 0.64 | 1.19 | 0.12 | 0.06 | 0.12 | 0.23 | 0.19 | 0.25 | 0.38 | 1.16 | 1.67 |
Source: XBRL data Armata Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 14, 2017.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ARMP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ARMP | - | - | -$192.18M | - | $139.4M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $211.94B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.49B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $60.30B |
| RVMD | $0 | - | -$1.13B | - | $41.76B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.44B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.91B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.22B |
ARMP FAQ
5 questionsIs ARMP profitable?
No. Armata Pharmaceuticals Inc. reported a net loss of $192.18M for the twelve months ended Jun 30, 2026.How much cash and debt does ARMP have?
Armata Pharmaceuticals Inc. reported $23.95M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ARMP free cash flow?
Armata Pharmaceuticals Inc. generated -$25.79M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$25.42M less capital expenditures.When did ARMP last report financial results?
The latest statements here come from Armata Pharmaceuticals Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this ARMP financial data come from?
Quantisnow builds these statements from the structured XBRL data Armata Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.